Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04006496 · ClinicalTrials.gov registry record · NA

AML Expressive Writing

A NA study, sponsored by Duke University.

Terminated
Registry status
NA
Development phase
15
Enrollment target

NCT04006496 is a NA study that was terminated before completion, run by Duke University. The registered enrollment target is 15 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04006496, a NA study, was terminated before completion, sponsored by Duke University.

TERMINATED
Registry status
NA
Development phase
15 participants
Enrollment target

Study Summary

A randomized, pilot feasibility and preliminary efficacy study to test such an intervention among hospitalized patients with AML who are receiving high-dose chemotherapy. Subjects randomized to the intervention arm will participate in a total of four, separate 1-hour expressive writing sessions that include the delivery of writing prompts, instructions, writing analyses, and coaching from a trained facilitator, delivered over the course of 2 weeks. Subjects randomized to the control arm of the study will receive standard care plus neutral writing prompts and instructions, but writing analyses and coaching from a trained facilitator will not be provided.

Interventions

  • BEHAVIORAL Expressive Writing Coaching

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2019-11-04
Est. Completion 2022-01-19
Phase NA

Sponsor

Duke University

1,725 total trials

What the Registry Record Tells You About NCT04006496

The ClinicalTrials.gov registry entry for NCT04006496 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Expressive Writing Coaching is the first listed.

NCT04006496 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04006496 about?

NCT04006496 is a clinical study titled "AML Expressive Writing". A randomized, pilot feasibility and preliminary efficacy study to test such an intervention among hospitalized patients with AML who are receiving high-dose chemotherapy. Subjects randomized to the intervention arm will participate in a total of four, separate 1-hour expressive writing sessions that...

What is the current status of trial NCT04006496?

This trial is currently terminated. It is a NA study. The enrollment target is 15 participants. The study started on 2019-11-04. Estimated completion is 2022-01-19.

What interventions are being tested in trial NCT04006496?

The interventions under investigation include: Expressive Writing Coaching (BEHAVIORAL).

Who is sponsoring clinical trial NCT04006496?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.